Motavizumab Withdrawn Phase 3 Trials for Wheezing Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00628303A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants